scholarly journals The evolution of regulated cell death pathways in animals and their evasion by pathogens

2022 ◽  
Vol 102 (1) ◽  
pp. 411-454
Author(s):  
Bart Tummers ◽  
Douglas R. Green

The coevolution of host-pathogen interactions underlies many human physiological traits associated with protection from or susceptibility to infections. Among the mechanisms that animals utilize to control infections are the regulated cell death pathways of pyroptosis, apoptosis, and necroptosis. Over the course of evolution these pathways have become intricate and complex, coevolving with microbes that infect animal hosts. Microbes, in turn, have evolved strategies to interfere with the pathways of regulated cell death to avoid eradication by the host. Here, we present an overview of the mechanisms of regulated cell death in Animalia and the strategies devised by pathogens to interfere with these processes. We review the molecular pathways of regulated cell death, their roles in infection, and how they are perturbed by viruses and bacteria, providing insights into the coevolution of host-pathogen interactions and cell death pathways.

2019 ◽  
Author(s):  
Ryan Richards ◽  
Hannah R. Schwartz ◽  
Mariah S. Stewart ◽  
Peter Cruz-Gordillo ◽  
Megan E. Honeywell ◽  
...  

ABSTRACTTherapeutic regimens for cancer generally involve drugs used in combinations. Most prior work has focused on identifying and understanding synergistic drug-drug interactions; however, understanding sources of antagonistic interactions remains an important and understudied issue. To enrich for antagonistic interactions and reveal common features of these drug combinations, we screened all pairwise combinations of drugs characterized as canonical activators of different forms of regulated cell death. We find that this network is strongly enriched for antagonistic interactions, and in particular, enriched for an extreme form of antagonism, which we call “single agent dominance”. Single agent dominance refers to antagonisms in which a two drug combination phenocopies one of the two agents. We find that dominance results from differences in the cell death onset time, with dominant drugs inducing death earlier and at faster rates than their suppressed counterparts. Finally, we explored the mechanisms by which parthanatotic agents dominate apoptotic agents, finding that dominance in this scenario is caused by mutually exclusive and conflicting use of PARP1. Taken together, our study reveals death activation kinetics as a predictive feature of antagonism, due to inhibitory crosstalk between cell death pathways.


2021 ◽  
Author(s):  
Suzette Palmer ◽  
Sruthi Chappidi ◽  
Chelsea Pinkham ◽  
Dustin C. Hancks

AbstractPathogen infection triggers host innate defenses which can lead to the activation of regulated cell death (RCD) pathways such as apoptosis. Given a key role in immunity, apoptotic effectors are often counteracted by pathogen-encoded antagonists. Mounting evidence indicates that programmed necrosis, which is mediated by the RIPK3/MLKL axis and termed necroptosis, evolved as a countermeasure to pathogen-mediated inhibition of apoptotic signaling. However, whether this emerging inflammatory RCD pathway functions primarily as a “back-up” or fundamental response remains inconclusive. We hypothesized that if necroptosis is an instrumental defense, then its effectors should display specific signatures associated with pathogen conflict that are rare in combination: rapid evolution, viral homolog hereafter virolog, and induction by cytokines (e.g. interferons). Our rapid evolution analysis across the necroptosis pathway revealed: 1) strong signatures of positive selection for RIPK3 and MLKL in primate genomes and to a lesser extent DAI/ZBP1, 2) elevated rates of amino acid substitution on multiple surfaces including the RIPK3/MLKL binding interface and 3) evidence supporting a means of activating RIPK3 independent of homotypic RHIM domain interactions. Interestingly, a poxvirus MLKL homolog has recently been identified that acts as a RIPK3 pseudosubstrate. Our findings indicate that poxvirus MLKLs are also subject to similar but distinct volatile patterns of evolution comparable to host necroptotic factors. Specifically, viral MLKLs have undergone numerous gains and losses in poxvirus evolution with some species harboring three distinct copies. Furthermore, we confirm that MLKL can be induced by cytokines like interferon gamma. In summary, MLKL displays all three hallmarks of pivotal immune factors of which only OAS1, but not other factors like cGAS, APOBEC3G, or PKR, exhibits. These data support the hypothesis that over evolutionary time, necroptosis has served as a key battleground during infection and is therefore, not an auxiliary response.SummaryRegulated cell death (RCD), such as apoptosis, is a common host defense against invading pathogens. Necroptosis, an inflammatory RCD pathway, is thought to have emerged as an auxiliary response when other cell death pathways are suppressed by pathogens during infection. In our analyses, we have identified genetic changes in host and viral factors associated with necroptosis that display signatures of adaptation and may have served as evolutionary countermeasures to shape infection outcomes. Consistent with repeated targeting by pathogen-encoded inhibitors, we found robust signatures of rapid evolution for the essential catalysts of necroptosis, RIPK3 and MLKL. Notably, an evolutionary signature specific to RIPK3 for a domain shared with other necroptotic factors suggests an undefined means to trigger this host defense pathway. In contrast, poxviruses appear to circumvent this pathway by constantly altering the number and nature of factors they deploy to suppress necroptosis including a mimic of MLKL, which was stolen from infected cells. Collectively, our findings provide new insights into host and viral genetics that may influence infection outcomes and the factors shaping the ability of pathogens to infect and spread to new species. Furthermore, these data support the notion that necroptosis is a fundamental, not auxiliary, host response during infection.


Author(s):  
Venkata Mahidhar Yenugonda ◽  
Ariana Waters ◽  
Sivaramakrishna Yadavalli ◽  
Diego Marzese ◽  
Surojeet Senugupta ◽  
...  

Author(s):  
Marwa Abd El-kader ◽  
Eman Hamza ◽  
Randa El-Gamal ◽  
Amira Sobhy Rashed Eladl ◽  
Eman Mohamad El Nashar ◽  
...  

2021 ◽  
Vol 12 (4) ◽  
Author(s):  
Effimia Christidi ◽  
Liam R. Brunham

AbstractDoxorubicin is a chemotherapeutic drug used for the treatment of various malignancies; however, patients can experience cardiotoxic effects and this has limited the use of this potent drug. The mechanisms by which doxorubicin kills cardiomyocytes has been elusive and despite extensive research the exact mechanisms remain unknown. This review focuses on recent advances in our understanding of doxorubicin induced regulated cardiomyocyte death pathways including autophagy, ferroptosis, necroptosis, pyroptosis and apoptosis. Understanding the mechanisms by which doxorubicin leads to cardiomyocyte death may help identify novel therapeutic agents and lead to more targeted approaches to cardiotoxicity testing.


2020 ◽  
Author(s):  
Christina M. Bebber ◽  
Emily S. Thomas ◽  
Zhiyi Chen ◽  
Jenny Stroh ◽  
Ariadne Androulidaki ◽  
...  

AbstractBi-allelic loss of TP53 and RB1 in treatment-naïve small cell lung cancer (SCLC) suggests strong selective pressure to inactivate regulated cell death pathways prior to therapy. Yet, which regulated cell death pathways remain available in treatment-naïve SCLC is unknown. Here, through systemic analysis of cell death pathway availability, we identify non-neuroendocrine (NE) and NE SCLC subtypes to segregate by their response to ferroptosis, a recently described iron-dependent type of regulated necrosis. While we identify that in treatment-naïve SCLC extrinsic apoptosis and necroptosis are incapacitated, we find non-NE SCLC to be exquisitely sensitive to ferroptosis induced through pharmacological and genetic means. Mechanistically, non-NE SCLC as opposed to NE SCLC presents with an oxygenated lipidome priming non-NE SCLC for ferroptosis. ASCL1+ NE SCLC, in turn, is resistant to ferroptosis but acquires selective addiction to the thioredoxin (TRX) anti-oxidant pathway. Importantly, co-cultures mimicking non-NE/NE intratumoral heterogeneity selectively deplete non-NE populations upon induction of ferroptosis while eliminating NE cell populations only upon TRX pathway. As a consequence, combined induction of ferroptosis and inhibition of the TRX pathway broadly kills established non-NE and NE tumors in xenografts and genetically engineered mouse models of SCLC. Moreover, patient-derived treatment-naïve and refractory NE SCLC models are selectively killed via this regime. In SCLC, combined low expression of GPX4 and TRX reductase 1 (TXNRD1) identifies a patient subset with drastically improved overall survival. These data identify ferroptosis as an SCLC subtype-specific vulnerability and suggest repurposing ferroptosis induction with TRX pathway inhibition to specifically address intratumoral NE/non-NE heterogeneity in SCLC.One Sentence SummaryThe SCLC non-neuroendocrine subtype is sensitive to ferroptosis


2018 ◽  
Vol 27 (6) ◽  
pp. 890-901 ◽  
Author(s):  
Antonio Bruni ◽  
Stefan Bornstein ◽  
Andreas Linkermann ◽  
A. M. James Shapiro

Clinical islet transplantation effectively restores euglycemia and corrects glycosylated hemoglobin in labile type 1 diabetes mellitus (T1DM). Despite marked improvements in islet transplantation outcomes, acute islet cell death remains a substantial obstacle that compromises long-term engraftment outcomes. Multiple organ donors are routinely required to achieve insulin independence. Therapeutic agents that ameliorate cell death and/or control injury-related inflammatory cascades offer potential to improve islet transplant success. Apoptotic cell death has been identified as a major contributor to cellular demise and therapeutic strategies that subvert initiation and consequences of apoptotic cell death have shown promise in pre-clinical models. Indeed, in numerous pathologies and diseases apoptosis has been the most extensively described form of regulated cell death. However, recent identification of novel, alternative regulated cell death pathways in other disease states and solid organ transplantation suggest that these additional pathways may also have substantial relevance in islet transplantation. These regulated, non-apoptotic cell death pathways exhibit distinct biochemical characteristics but have yet to be fully characterized within islet transplantation. We review herein the various regulated cell death pathways and highlight their relative potential contributions to islet viability, engraftment failure and islet dysfunction.


2009 ◽  
Vol 8 (6) ◽  
pp. 1421-1429 ◽  
Author(s):  
Nidhish Sasi ◽  
Misun Hwang ◽  
Jerry Jaboin ◽  
Ildiko Csiki ◽  
Bo Lu

Sign in / Sign up

Export Citation Format

Share Document